{{!--
  Investigator's Brochure - Generic Product
  Section 8: Marketed Experience
  
  Template for ICH E6 (R2) compliant IB Section 8
  
  Data Sources:
  - adverse_events (post-marketing data)
  - label (warnings, precautions)
  - literature (post-marketing studies)
  
  Variables:
  - compound_name: string
  - generic_name: string
  - rld_brand_name: string
  - product_type: string
  - adverse_events: AdverseEvent[]
  - label: Label
  - literature: Literature[]
--}}

# 8. MARKETED EXPERIENCE

## 8.1 Overview

{{#if eq product_type "generic"}}
{{compound_name}} is a generic formulation bioequivalent to the Reference Listed Drug (RLD) {{rld_brand_name}}. The marketed experience described in this section is based on the RLD's post-marketing surveillance data, as generic products share the same safety profile as their reference products when bioequivalence has been demonstrated.
{{else}}
{{compound_name}} has been marketed for {{#if label.approval_date}}{{yearsince label.approval_date}} years{{else}}[duration]{{/if}}. This section summarizes the post-marketing experience, including adverse events, safety signals, and real-world evidence accumulated since market approval.
{{/if}}

---

## 8.2 Marketing History

### 8.2.1 Approval and Launch

{{#if label}}
**Initial FDA Approval:** {{#if label.approval_date}}{{date label.approval_date "YYYY-MM-DD"}}{{else}}[Approval date]{{/if}}

**Application Number:** {{#if label.application_number}}{{label.application_number}}{{else}}[Application number]{{/if}}

**Marketing Status:** {{#if label.marketing_status}}{{capitalize label.marketing_status}}{{else}}Actively marketed{{/if}}
{{else}}
**Initial FDA Approval:** [Approval date]

**Application Number:** [Application number]

**Marketing Status:** [Status]
{{/if}}

### 8.2.2 Geographic Distribution

{{#if label.international_approvals}}
**Markets:** {{compound_name}} is approved and marketed in the following regions:

{{#each label.international_approvals}}
- **{{this.region}}:** {{this.status}}{{#if this.approval_date}} (Since {{date this.approval_date "YYYY"}}){{/if}}
{{/each}}
{{else}}
**Markets:** [List countries/regions where product is marketed]
{{/if}}

### 8.2.3 Patient Exposure

{{#if label.patient_exposure}}
**Estimated Patient Exposure:** {{label.patient_exposure}}

**Prescription Volume:** {{#if label.prescription_volume}}{{label.prescription_volume}}{{else}}[Volume data]{{/if}}
{{else}}
**Estimated Patient Exposure:** [Number of patients exposed since approval]

**Prescription Volume:** [Annual prescription data]
{{/if}}

---

## 8.3 Post-Marketing Adverse Events

### 8.3.1 Adverse Event Reporting

{{#if adverse_events}}
Post-marketing surveillance has identified the following adverse events reported in association with {{compound_name}} use:

**Total Reports:** {{length adverse_events}} adverse event types documented

**Data Source:** FDA Adverse Event Reporting System (FAERS){{#if label.source}}, {{label.source}}{{/if}}

**Reporting Period:** {{#if adverse_events.[0].report_date}}Since {{date adverse_events.[0].report_date "YYYY"}}{{else}}[Period]{{/if}}
{{else}}
Post-marketing adverse event data is derived from spontaneous reporting systems and post-marketing studies.

[Summarize adverse event reporting system and data sources]
{{/if}}

### 8.3.2 Common Adverse Events

{{#if adverse_events}}
The following adverse events have been reported with the highest frequency:

| Adverse Event | Incidence | Severity | Outcome |
|---------------|-----------|----------|---------|
{{#each adverse_events}}
{{#if lte @index 9}}
| {{this.event_name}} | {{#if this.incidence_pct}}{{decimal this.incidence_pct 2}}%{{else}}[Rate]{{/if}} | {{#if this.severity}}{{capitalize this.severity}}{{else}}[Severity]{{/if}} | {{#if this.outcome}}{{this.outcome}}{{else}}[Outcome]{{/if}} |
{{/if}}
{{/each}}

**Note:** Incidence rates are based on spontaneous reporting and may not reflect true population incidence.
{{else}}
[Provide table of most commonly reported adverse events with incidence rates, severity, and outcomes]
{{/if}}

### 8.3.3 Serious Adverse Events

{{#if adverse_events}}
**Serious Adverse Events (SAEs):**

{{#each adverse_events}}
{{#if eq this.serious true}}
- **{{this.event_name}}:** {{#if this.description}}{{this.description}}{{else}}[Description]{{/if}}
  - Incidence: {{#if this.incidence_pct}}{{decimal this.incidence_pct 2}}%{{else}}[Rate]{{/if}}
  - Outcome: {{#if this.outcome}}{{this.outcome}}{{else}}[Outcome]{{/if}}
  - Causality: {{#if this.causality}}{{this.causality}}{{else}}[Assessment]{{/if}}

{{/if}}
{{/each}}
{{else}}
[Describe serious adverse events reported post-marketing, including:
- Event description
- Incidence rate
- Outcomes
- Causality assessment]
{{/if}}

### 8.3.4 Adverse Events of Special Interest

{{#if label.sections.warnings_and_precautions}}
**Warnings and Precautions:**

{{label.sections.warnings_and_precautions}}
{{else}}
[Describe adverse events of special interest that have emerged from post-marketing experience]

**Categories:**
- Cardiovascular events
- Hepatotoxicity
- Hypersensitivity reactions
- Drug interactions
- Special populations
{{/if}}

---

## 8.4 Safety Signals and Label Updates

### 8.4.1 Post-Marketing Safety Signals

{{#if label.safety_updates}}
**Safety Signals Identified:**

{{#each label.safety_updates}}
- **{{this.signal}}** ({{date this.date "YYYY-MM-DD"}})
  - Description: {{this.description}}
  - Action Taken: {{this.action}}
{{/each}}
{{else}}
[Describe any safety signals identified through post-marketing surveillance]

**Signal Detection Methods:**
- Spontaneous reporting analysis
- Data mining
- Literature review
- Regulatory authority communications
{{/if}}

### 8.4.2 Label Changes

{{#if label.label_changes}}
**Significant Label Updates:**

{{#each label.label_changes}}
- **{{date this.date "YYYY-MM-DD"}}:** {{this.change_description}}
  - Section Affected: {{this.section}}
  - Reason: {{this.reason}}
{{/each}}
{{else}}
[Describe significant label changes made based on post-marketing data]

**Types of Changes:**
- New warnings or precautions
- Contraindications
- Dosing modifications
- Drug interaction updates
- Special population information
{{/if}}

### 8.4.3 Regulatory Actions

{{#if label.regulatory_actions}}
**Regulatory Actions Taken:**

{{#each label.regulatory_actions}}
- **{{this.action_type}}** ({{date this.date "YYYY-MM-DD"}})
  - Authority: {{this.authority}}
  - Description: {{this.description}}
  - Impact: {{this.impact}}
{{/each}}
{{else}}
[Describe any regulatory actions taken based on post-marketing data]

**Potential Actions:**
- Safety communications
- Risk Evaluation and Mitigation Strategies (REMS)
- Market withdrawals
- Use restrictions
{{/if}}

---

## 8.5 Post-Marketing Studies

### 8.5.1 Phase 4 Studies

{{#if literature}}
**Post-Approval Studies:**

{{#each literature}}
{{#if eq this.study_phase "Phase 4"}}
**Study:** {{this.title}}

- **Authors:** {{join this.authors ", "}}
- **Journal:** {{this.journal}}{{#if this.publication_date}} ({{this.publication_date}}){{/if}}
- **PMID:** {{this.pmid}}
- **Key Findings:** {{#if this.abstract}}{{truncate this.abstract 200}}{{else}}[Summary]{{/if}}

{{/if}}
{{/each}}
{{else}}
[Describe Phase 4 post-marketing studies conducted]

**Study Types:**
- Long-term safety studies
- Real-world effectiveness studies
- Special population studies
- Drug interaction studies
{{/if}}

### 8.5.2 Observational Studies

{{#if literature}}
**Real-World Evidence:**

{{#each literature}}
{{#if includes this.keywords "observational"}}
**Study:** {{this.title}}

- **Design:** {{#if this.study_design}}{{this.study_design}}{{else}}Observational{{/if}}
- **Population:** {{#if this.population_size}}N={{this.population_size}}{{else}}[Size]{{/if}}
- **Duration:** {{#if this.follow_up}}{{this.follow_up}}{{else}}[Duration]{{/if}}
- **Findings:** {{#if this.abstract}}{{truncate this.abstract 150}}{{else}}[Summary]{{/if}}

{{/if}}
{{/each}}
{{else}}
[Describe observational studies and real-world evidence]

**Data Sources:**
- Electronic health records
- Claims databases
- Patient registries
- Pharmacovigilance databases
{{/if}}

---

## 8.6 Special Populations

### 8.6.1 Pediatric Experience

{{#if label.sections.pediatric_use}}
{{label.sections.pediatric_use}}
{{else}}
[Describe post-marketing experience in pediatric populations]

**Considerations:**
- Safety profile
- Dosing adjustments
- Efficacy observations
- Adverse events
{{/if}}

### 8.6.2 Geriatric Experience

{{#if label.sections.geriatric_use}}
{{label.sections.geriatric_use}}
{{else}}
[Describe post-marketing experience in geriatric populations]

**Considerations:**
- Safety profile
- Dose adjustments
- Drug interactions
- Adverse events
{{/if}}

### 8.6.3 Pregnancy and Lactation

{{#if label.sections.pregnancy}}
{{label.sections.pregnancy}}
{{else}}
[Describe post-marketing experience in pregnancy and lactation]

**Pregnancy:**
- Exposure data
- Outcomes
- Risk assessment

**Lactation:**
- Excretion in breast milk
- Effects on nursing infant
- Recommendations
{{/if}}

### 8.6.4 Renal and Hepatic Impairment

{{#if label.sections.renal_impairment}}
**Renal Impairment:**
{{label.sections.renal_impairment}}
{{else}}
**Renal Impairment:** [Describe experience in patients with renal impairment]
{{/if}}

{{#if label.sections.hepatic_impairment}}
**Hepatic Impairment:**
{{label.sections.hepatic_impairment}}
{{else}}
**Hepatic Impairment:** [Describe experience in patients with hepatic impairment]
{{/if}}

---

## 8.7 Drug Interactions

### 8.7.1 Post-Marketing Drug Interaction Reports

{{#if adverse_events}}
**Reported Drug Interactions:**

{{#each adverse_events}}
{{#if this.drug_interaction}}
- **{{this.interacting_drug}}:** {{this.interaction_description}}
  - Severity: {{#if this.severity}}{{capitalize this.severity}}{{else}}[Severity]{{/if}}
  - Management: {{#if this.management}}{{this.management}}{{else}}[Recommendations]{{/if}}

{{/if}}
{{/each}}
{{else}}
[Describe drug interactions identified through post-marketing surveillance]
{{/if}}

### 8.7.2 Clinically Significant Interactions

{{#if label.sections.drug_interactions}}
{{label.sections.drug_interactions}}
{{else}}
[Describe clinically significant drug interactions]

**Categories:**
- Pharmacokinetic interactions
- Pharmacodynamic interactions
- Contraindicated combinations
- Dose adjustment requirements
{{/if}}

---

## 8.8 Medication Errors

{{#if label.medication_errors}}
**Reported Medication Errors:**

{{#each label.medication_errors}}
- **Error Type:** {{this.error_type}}
  - Description: {{this.description}}
  - Prevention: {{this.prevention_strategy}}
{{/each}}
{{else}}
[Describe medication errors reported post-marketing]

**Common Error Types:**
- Dosing errors
- Administration errors
- Dispensing errors
- Look-alike/sound-alike issues
{{/if}}

---

## 8.9 Risk Management

### 8.9.1 Risk Minimization Measures

{{#if label.risk_management}}
{{label.risk_management}}
{{else}}
[Describe risk minimization measures implemented]

**Measures:**
- Prescriber education
- Patient information materials
- Restricted distribution programs
- Monitoring requirements
{{/if}}

### 8.9.2 REMS (Risk Evaluation and Mitigation Strategy)

{{#if label.rems}}
**REMS Status:** {{label.rems.status}}

**REMS Components:**
{{#each label.rems.components}}
- {{this}}
{{/each}}
{{else}}
**REMS Status:** {{#if label.has_rems}}Active{{else}}Not required{{/if}}

[Describe REMS if applicable]
{{/if}}

---

## 8.10 Summary

{{#if eq product_type "generic"}}
The marketed experience with {{compound_name}} is based on the extensive post-marketing data for the RLD {{rld_brand_name}}. As a bioequivalent generic product, {{compound_name}} is expected to have the same safety and efficacy profile as the RLD.
{{else}}
{{compound_name}} has been marketed for {{#if label.approval_date}}{{yearsince label.approval_date}} years{{else}}[duration]{{/if}}, with {{#if label.patient_exposure}}{{label.patient_exposure}}{{else}}[number]{{/if}} patients exposed worldwide.
{{/if}}

**Key Points:**
- {{#if adverse_events}}{{length adverse_events}} adverse event types documented{{else}}Comprehensive adverse event monitoring{{/if}}
- {{#if label.safety_updates}}{{length label.safety_updates}} safety signals identified{{else}}Ongoing safety surveillance{{/if}}
- {{#if label.label_changes}}{{length label.label_changes}} label updates{{else}}Regular label review{{/if}}
- {{#if literature}}{{length literature}} post-marketing studies{{else}}Continued research{{/if}}

The post-marketing experience supports the continued safe use of {{compound_name}} when prescribed according to approved labeling and with appropriate monitoring.

---

## 8.11 Data Sources

This section was compiled from the following sources:

{{#if adverse_events}}
- **Adverse Events:** FDA FAERS ({{length adverse_events}} events)
{{/if}}
{{#if label}}
- **Label Information:** {{label.source}} ({{label.effective_date}})
{{/if}}
{{#if literature}}
- **Literature:** {{length literature}} post-marketing publications
{{/if}}
{{#if eq product_type "generic"}}
- **RLD Data:** Based on {{rld_brand_name}} post-marketing experience
{{/if}}

**Confidence Level:** {{#if adverse_events.confidence}}{{capitalize adverse_events.confidence}}{{else}}High{{/if}}

---

*This section complies with ICH E6 (R2) guidelines for Investigator's Brochure content.*
